Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Presented at the ADA 85th Scientific Sessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Cagrilintide and semaglutide together drive record weight loss in global trial